Attorney Joshua S. Bauchner, Chair of the Cannabis and Psychedelics Practice Group, plays a crucial role defending positions that propose the rescheduling of Psilocybin, serving as the principal author in a pro-bono amicus curiae brief. The brief was filed on behalf of the National Organization for the Reform of Marijuana Laws (NORML) in response to the case of Dr. Sunil Aggarwal, MD, PhD; Advanced Integrative Medical Science Institute, PLLC v. U.S. Drug Enforcement Administration et al.
The case is a noteworthy development in the debate concerning Psilocybin’s medicinal use and its legal status. Originating in magic mushrooms, Psilocybin has begun to gain recognition in the scientific community for its potential benefits. The rescheduling of Psilocybin from a Schedule I to a Schedule II substance could revolutionize its use in treatment plans for mental health disorders.
The current legal status of Psilocybin as a Schedule I substance, as designated under the Controlled Substances Act, restricts its availability and research due to the stringent criteria attached to Schedule I substances, namely a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision.
A successful rescheduling based off the brief written by Bauchner in support of Dr. Sunil Aggarwal and the Advanced Integrative Medical Science Institute could potentially pave the way for more comprehensive research and wider availability of Psilocybin for medical use.
For more comprehensive details about this amicus curiae brief, refer directly to the original document at the JdSupra website.